Floatz logo

Luvometinib

KRAS-mutated

Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.Small moleculePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

1 Active assets in the KRAS-mutated cohort.

Asset / SponsorPhaseRating
Catequentinib
Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
Phase 2CCC

Same molecule, other indications

Luvometinib is also rated in:

non-small cell lung carcinomaDormant
CCC
Indicative ·
53 / 100
View asset →
metastatic neoplasmDormant
CCC
Indicative ·
53 / 100
View asset →
melanomaDormant
C
Indicative ·
37 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →